Home›Insulin Glargine-Aglr

Insulin Glargine-Aglr

Also known as: Rezvoglar Kwikpen

Insulin Analog

Route: Subcutaneous

Check Insulin Glargine-Aglr Interactions →

39 interactions on record

Insulin Glargine-Aglr has 39 known drug interactions based on U.S. FDA drug labeling data. Notable interactions include combinations with Acidifying Agents, Albuterol, Alcohol. Patients taking Insulin Glargine-Aglr should inform their healthcare provider of all current medications — including over-the-counter drugs and supplements — to avoid potentially harmful combinations. Data sourced from OpenFDA and the NIH National Library of Medicine.

Total: 39
Moderate: 37

Moderate (37)

Insulin Glargine-Aglr + Acidifying Agents— May increase risk of hypoglycemia. Dosage reductions and increased glucose monitoring may be required.
Insulin Glargine-Aglr + Albuterol— Sympathomimetic agent that may decrease blood glucose lowering effect. Dosage increases and increased glucose monitoring…
Insulin Glargine-Aglr + Alcohol— May increase or decrease blood glucose lowering effect. Dose adjustment and increased glucose monitoring may be required…
Insulin Glargine-Aglr + Angiotensin Ii— May increase risk of hypoglycemia. Dosage reductions and increased frequency of glucose monitoring may be required.
Insulin Glargine-Aglr + Clonidine— May increase or decrease blood glucose lowering effect and blunt signs/symptoms of hypoglycemia. Dose adjustment and inc…
Insulin Glargine-Aglr + Clozapine— Atypical antipsychotic that may decrease blood glucose lowering effect. Dosage increases and increased glucose monitorin…
Insulin Glargine-Aglr + Corticosteroids— May decrease blood glucose lowering effect. Dosage increases and increased glucose monitoring may be required.
Insulin Glargine-Aglr + Danazol— May decrease blood glucose lowering effect. Dosage increases and increased glucose monitoring may be required.
Insulin Glargine-Aglr + Disopyramide— May increase risk of hypoglycemia. Dosage reductions and increased frequency of glucose monitoring may be required.
Insulin Glargine-Aglr + Diuretics— May decrease blood glucose lowering effect. Dosage increases and increased glucose monitoring may be required.
Insulin Glargine-Aglr + Epinephrine— Sympathomimetic agent that may decrease blood glucose lowering effect. Dosage increases and increased glucose monitoring…
Insulin Glargine-Aglr + Estrogens— May decrease blood glucose lowering effect. Dosage increases and increased glucose monitoring may be required.
Insulin Glargine-Aglr + Fibrates— May increase risk of hypoglycemia. Dosage reductions and increased frequency of glucose monitoring may be required.
Insulin Glargine-Aglr + Fluoxetine— May increase risk of hypoglycemia. Dosage reductions and increased frequency of glucose monitoring may be required.
Insulin Glargine-Aglr + Glucagon— May decrease blood glucose lowering effect. Dosage increases and increased glucose monitoring may be required.
Insulin Glargine-Aglr + Guanethidine— May blunt signs and symptoms of hypoglycemia. Increased frequency of glucose monitoring may be required.
Insulin Glargine-Aglr + Isoniazid— May decrease blood glucose lowering effect. Dosage increases and increased glucose monitoring may be required.
Insulin Glargine-Aglr + Liraglutide— May increase risk of hypoglycemia. Dosage reductions and increased frequency of glucose monitoring may be required.
Insulin Glargine-Aglr + Lithium— May increase or decrease blood glucose lowering effect. Dose adjustment and increased glucose monitoring may be required…
Insulin Glargine-Aglr + Macrolide Antibiotics— May increase risk of hypoglycemia. Dosage reductions and increased glucose monitoring may be required.
Insulin Glargine-Aglr + Mao Inhibitors— May increase risk of hypoglycemia. Dosage reductions and increased frequency of glucose monitoring may be required.
Insulin Glargine-Aglr + Monoamine Oxidase Inhibitors (Maois)— May increase risk of hypoglycemia. Dosage reductions and increased frequency of glucose monitoring may be required.
Insulin Glargine-Aglr + Niacin— May decrease blood glucose lowering effect. Dosage increases and increased glucose monitoring may be required.
Insulin Glargine-Aglr + Nonselective Beta-Adrenergic Antagonists— May increase or decrease blood glucose lowering effect and blunt signs/symptoms of hypoglycemia. Dose adjustment and inc…
Insulin Glargine-Aglr + Octreotide— Somatostatin analog that may increase risk of hypoglycemia. Dosage reductions and increased glucose monitoring may be re…
Insulin Glargine-Aglr + Olanzapine— Atypical antipsychotic that may decrease blood glucose lowering effect. Dosage increases and increased glucose monitorin…
Insulin Glargine-Aglr + Oral Contraceptives— May decrease blood glucose lowering effect. Dosage increases and increased glucose monitoring may be required.
Insulin Glargine-Aglr + Pentamidine— May cause hypoglycemia sometimes followed by hyperglycemia. Dose adjustment and increased glucose monitoring may be requ…
Insulin Glargine-Aglr + Pentoxifylline— May increase risk of hypoglycemia. Dosage reductions and increased frequency of glucose monitoring may be required.
Insulin Glargine-Aglr + Phenothiazines— May decrease blood glucose lowering effect. Dosage increases and increased glucose monitoring may be required.
Insulin Glargine-Aglr + Pramlintide— May increase risk of hypoglycemia. Dosage reductions and increased frequency of glucose monitoring may be required.
Insulin Glargine-Aglr + Protease Inhibitors— May decrease blood glucose lowering effect. Dosage increases and increased glucose monitoring may be required.
Insulin Glargine-Aglr + Reserpine— May blunt signs and symptoms of hypoglycemia. Increased frequency of glucose monitoring may be required.
Insulin Glargine-Aglr + Salicylates— May increase risk of hypoglycemia. Dosage reductions and increased frequency of glucose monitoring may be required.
Insulin Glargine-Aglr + Somatropin— May decrease blood glucose lowering effect. Dosage increases and increased glucose monitoring may be required.
Insulin Glargine-Aglr + Terbutaline— Sympathomimetic agent that may decrease blood glucose lowering effect. Dosage increases and increased glucose monitoring…
Insulin Glargine-Aglr + Thyroid Hormones— May decrease blood glucose lowering effect. Dosage increases and increased glucose monitoring may be required.

Insulin Glargine-Aglr + Acidifying Agents🟡Moderate

May increase risk of hypoglycemia. Dosage reductions and increased glucose monitoring may be required.

Insulin Glargine-Aglr + Albuterol🟡Moderate

Sympathomimetic agent that may decrease blood glucose lowering effect. Dosage increases and increased glucose monitoring may be required.

Insulin Glargine-Aglr + Alcohol🟡Moderate

May increase or decrease blood glucose lowering effect. Dose adjustment and increased glucose monitoring may be required.

Insulin Glargine-Aglr + Angiotensin Ii🟡Moderate

May increase risk of hypoglycemia. Dosage reductions and increased frequency of glucose monitoring may be required.

Insulin Glargine-Aglr + Clonidine🟡Moderate

May increase or decrease blood glucose lowering effect and blunt signs/symptoms of hypoglycemia. Dose adjustment and increased glucose monitoring required.

Insulin Glargine-Aglr + Clozapine🟡Moderate

Atypical antipsychotic that may decrease blood glucose lowering effect. Dosage increases and increased glucose monitoring may be required.

Insulin Glargine-Aglr + Corticosteroids🟡Moderate

May decrease blood glucose lowering effect. Dosage increases and increased glucose monitoring may be required.

Insulin Glargine-Aglr + Danazol🟡Moderate

May decrease blood glucose lowering effect. Dosage increases and increased glucose monitoring may be required.

Insulin Glargine-Aglr + Disopyramide🟡Moderate

May increase risk of hypoglycemia. Dosage reductions and increased frequency of glucose monitoring may be required.

Insulin Glargine-Aglr + Diuretics🟡Moderate

May decrease blood glucose lowering effect. Dosage increases and increased glucose monitoring may be required.

Insulin Glargine-Aglr + Epinephrine🟡Moderate

Sympathomimetic agent that may decrease blood glucose lowering effect. Dosage increases and increased glucose monitoring may be required.

Insulin Glargine-Aglr + Estrogens🟡Moderate

May decrease blood glucose lowering effect. Dosage increases and increased glucose monitoring may be required.

Insulin Glargine-Aglr + Fibrates🟡Moderate

May increase risk of hypoglycemia. Dosage reductions and increased frequency of glucose monitoring may be required.

Insulin Glargine-Aglr + Fluoxetine🟡Moderate

May increase risk of hypoglycemia. Dosage reductions and increased frequency of glucose monitoring may be required.

Insulin Glargine-Aglr + Glucagon🟡Moderate

May decrease blood glucose lowering effect. Dosage increases and increased glucose monitoring may be required.

Insulin Glargine-Aglr + Guanethidine🟡Moderate

May blunt signs and symptoms of hypoglycemia. Increased frequency of glucose monitoring may be required.

Insulin Glargine-Aglr + Isoniazid🟡Moderate

May decrease blood glucose lowering effect. Dosage increases and increased glucose monitoring may be required.

Insulin Glargine-Aglr + Liraglutide🟡Moderate

May increase risk of hypoglycemia. Dosage reductions and increased frequency of glucose monitoring may be required.

Insulin Glargine-Aglr + Lithium🟡Moderate

May increase or decrease blood glucose lowering effect. Dose adjustment and increased glucose monitoring may be required.

Insulin Glargine-Aglr + Macrolide Antibiotics🟡Moderate

May increase risk of hypoglycemia. Dosage reductions and increased glucose monitoring may be required.

Insulin Glargine-Aglr + Mao Inhibitors🟡Moderate

May increase risk of hypoglycemia. Dosage reductions and increased frequency of glucose monitoring may be required.

Insulin Glargine-Aglr + Monoamine Oxidase Inhibitors (Maois)🟡Moderate

May increase risk of hypoglycemia. Dosage reductions and increased frequency of glucose monitoring may be required.

Insulin Glargine-Aglr + Niacin🟡Moderate

May decrease blood glucose lowering effect. Dosage increases and increased glucose monitoring may be required.

Insulin Glargine-Aglr + Nonselective Beta-Adrenergic Antagonists🟡Moderate

May increase or decrease blood glucose lowering effect and blunt signs/symptoms of hypoglycemia. Dose adjustment and increased glucose monitoring required.

Insulin Glargine-Aglr + Octreotide🟡Moderate

Somatostatin analog that may increase risk of hypoglycemia. Dosage reductions and increased glucose monitoring may be required.

Insulin Glargine-Aglr + Olanzapine🟡Moderate

Atypical antipsychotic that may decrease blood glucose lowering effect. Dosage increases and increased glucose monitoring may be required.

Insulin Glargine-Aglr + Oral Contraceptives🟡Moderate

May decrease blood glucose lowering effect. Dosage increases and increased glucose monitoring may be required.

Insulin Glargine-Aglr + Pentamidine🟡Moderate

May cause hypoglycemia sometimes followed by hyperglycemia. Dose adjustment and increased glucose monitoring may be required.

Insulin Glargine-Aglr + Pentoxifylline🟡Moderate

May increase risk of hypoglycemia. Dosage reductions and increased frequency of glucose monitoring may be required.

Insulin Glargine-Aglr + Phenothiazines🟡Moderate

May decrease blood glucose lowering effect. Dosage increases and increased glucose monitoring may be required.

Insulin Glargine-Aglr + Pramlintide🟡Moderate

May increase risk of hypoglycemia. Dosage reductions and increased frequency of glucose monitoring may be required.

Insulin Glargine-Aglr + Protease Inhibitors🟡Moderate

May decrease blood glucose lowering effect. Dosage increases and increased glucose monitoring may be required.

Insulin Glargine-Aglr + Reserpine🟡Moderate

May blunt signs and symptoms of hypoglycemia. Increased frequency of glucose monitoring may be required.

Insulin Glargine-Aglr + Salicylates🟡Moderate

May increase risk of hypoglycemia. Dosage reductions and increased frequency of glucose monitoring may be required.

Insulin Glargine-Aglr + Somatropin🟡Moderate

May decrease blood glucose lowering effect. Dosage increases and increased glucose monitoring may be required.

Insulin Glargine-Aglr + Terbutaline🟡Moderate

Sympathomimetic agent that may decrease blood glucose lowering effect. Dosage increases and increased glucose monitoring may be required.

Insulin Glargine-Aglr + Thyroid Hormones🟡Moderate

May decrease blood glucose lowering effect. Dosage increases and increased glucose monitoring may be required.

Insulin Glargine-Aglr + Acetazolamideℹ️Unknown

Table 8: Clinically Significant Drug Interactions with REZVOGLAR Drugs that May Increase the Risk of Hypoglycemia Drugs: Antidiabetic agents, ACE inhibitors, angiotensin II receptor blocking agents, disopyramide, fibrates, fluoxetine, monoamine oxidase inhibitors, pentoxifylline, pramlintide, salicylates, somatostatin analogs (e.g., octreotide), sulfonamide antibiotics.

Insulin Glargine-Aglr + Somatostatinℹ️Unknown

Data sourced from U.S. FDA drug labeling via openFDA and the NIH National Library of Medicine. For informational purposes only. Always consult your pharmacist or physician.